Zacks: Analysts Anticipate CareDx Inc (NASDAQ:CDNA) to Announce -$0.11 EPS

Equities research analysts predict that CareDx Inc (NASDAQ:CDNA) will report ($0.11) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for CareDx’s earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.08). CareDx posted earnings per share of $0.02 during the same quarter last year, which indicates a negative year over year growth rate of 650%. The business is expected to issue its next earnings results on Thursday, October 29th.

Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover CareDx.

CareDx (NASDAQ:CDNA) last released its earnings results on Tuesday, August 4th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. CareDx had a negative return on equity of 13.58% and a negative net margin of 12.66%. The company had revenue of $41.80 million during the quarter, compared to the consensus estimate of $35.61 million. The company’s revenue for the quarter was up 32.9% on a year-over-year basis.

Several research analysts have weighed in on the stock. BidaskClub lowered shares of CareDx from a “buy” rating to a “hold” rating in a research report on Tuesday, August 11th. BTIG Research raised their price objective on CareDx from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Zacks Investment Research cut CareDx from a “hold” rating to a “sell” rating in a report on Monday, August 10th. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 target price on shares of CareDx in a report on Monday, August 10th. Finally, Raymond James lifted their price target on CareDx from $40.00 to $42.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $43.38.

In other news, CEO Peter Maag sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $31.68, for a total value of $316,800.00. Following the completion of the transaction, the chief executive officer now directly owns 431,974 shares of the company’s stock, valued at $13,684,936.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 51,190 shares of company stock valued at $1,774,847. Insiders own 3.10% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers grew its stake in CareDx by 0.7% in the 1st quarter. Rhumbline Advisers now owns 57,452 shares of the company’s stock worth $1,254,000 after acquiring an additional 374 shares during the period. State of Wisconsin Investment Board lifted its stake in shares of CareDx by 0.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 64,000 shares of the company’s stock worth $2,268,000 after purchasing an additional 600 shares during the period. AQR Capital Management LLC boosted its holdings in shares of CareDx by 7.3% during the second quarter. AQR Capital Management LLC now owns 13,635 shares of the company’s stock worth $483,000 after purchasing an additional 929 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of CareDx in the second quarter valued at $36,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of CareDx by 58.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,817 shares of the company’s stock valued at $61,000 after purchasing an additional 1,038 shares during the period.

Shares of NASDAQ CDNA traded up $0.44 during midday trading on Wednesday, hitting $34.19. The company had a trading volume of 348,475 shares, compared to its average volume of 669,045. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -77.70 and a beta of 1.00. CareDx has a twelve month low of $13.04 and a twelve month high of $37.54. The business has a 50-day simple moving average of $33.23 and a two-hundred day simple moving average of $29.05. The company has a quick ratio of 4.26, a current ratio of 4.42 and a debt-to-equity ratio of 0.07.

About CareDx

CareDx, Inc, a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients.

Recommended Story: Buy Rating

Get a free copy of the Zacks research report on CareDx (CDNA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with's FREE daily email newsletter.